The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome

NCT04572477 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Post-stroke Dementia, Vascular Mild Cognitive Impairment

Interventions

DRUG: [18F]THK-5351
DRUG: [18F]AV-45

Sponsor

Chang Gung Memorial Hospital